AMRN - Amarin Corporation plc

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
2.89
+0.04 (+1.40%)
As of 12:12PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close2.85
Open2.85
Bid2.87 x 800
Ask2.88 x 3000
Day's Range2.78 - 2.92
52 Week Range2.35 - 4.60
Volume1,314,337
Avg. Volume3,419,460
Market Cap849.472M
Beta1.41
PE Ratio (TTM)N/A
EPS (TTM)-0.33
Earnings DateMay 4, 2017 - May 8, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.60
Trade prices are not sourced from all markets
  • Benzinga4 days ago

    The Week Ahead In Biotech (Sept. 16-22): Conferences, PDUFA Dates, Clinical Trial Results And IPOs

    Biotech were trending mostly sideways in the week ending Sept. 14 after posting weekly gains in the previous two weeks. Notwithstanding the overall muted sentiment, there was some activity in reaction ...

  • GlobeNewswire8 days ago

    REDUCE-IT™ Trial Primary Results Accepted for Presentation at 2018 Scientific Sessions of American Heart Association

    BEDMINSTER, N.J. and DUBLIN, Ireland, Sept. 12, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced that the primary results of Amarin’s cardiovascular outcomes study of Vascepa, the REDUCE-IT study, have been accepted for presentation at the 2018 Scientific Sessions of American Heart Association (AHA) on November 10, 2018 in Chicago, Illinois.  The presentation, classified as late-breaking clinical trial results, is scheduled to commence at 2:16 pm Central Time and listed as Main Event 1 for that timeframe.  A link to this notice is provided at: http://www.abstractsonline.com/pp8/#!/4682/presentation/59402. This acceptance as a presentation of late-breaking clinical trial results is based on the ability of REDUCE-IT to address a critical question in cardiovascular prevention.  The AHA has reviewed the design of the REDUCE-IT study, however, they have not yet seen the results of the study.  As Amarin has guided in the past, topline results of this study are anticipated to be made public prior to the end of this month, September 2018.

  • What Does Amarin Corporation plc’s (NASDAQ:AMRN) Ownership Structure Look Like?
    Simply Wall St.9 days ago

    What Does Amarin Corporation plc’s (NASDAQ:AMRN) Ownership Structure Look Like?

    A look at the shareholders of Amarin Corporation plc (NASDAQ:AMRN) can tell us which group is most powerful. Insiders often own a large chunk of younger, smaller, companies while hugeRead More...

  • Motley Fool12 days ago

    Will Amarin Reward Patient Investors?

    Results from a pivotal cardiovascular study are expected soon.

  • Motley Fool14 days ago

    A New Deal Moves MannKind Back From the Brink

    A new cash lifeline from United Therapeutics buys the diabetes drugmaker more time to increase sales of its inhaled insulin. Also, make-or-break news is fast approaching for cardiovascular drugmaker Amarin.

  • 3 Biotech Stocks That Still Have Major Catalysts in September
    Motley Fool15 days ago

    3 Biotech Stocks That Still Have Major Catalysts in September

    Clinical trial results on the way could change the way investors feel about these biotech stocks before the leaves start falling.

  • Why Amarin Corporation Skyrocketed 23.9% in August
    Motley Fool17 days ago

    Why Amarin Corporation Skyrocketed 23.9% in August

    Market-moving data for its only commercial-stage drug is on deck.

  • Benzinga18 days ago

    The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials And Earnings

    The biotech sector notched strong gains last week, capitalizing on the positive overall market sentiment, set in motion by the trade deal between the U.S. and Mexico. Here are a few catalysts that could ...

  • 3 Biotech Stocks That Could Soar Next Week
    Motley Fool18 days ago

    3 Biotech Stocks That Could Soar Next Week

    Amarin Corporation, CRISPR Therapeutics, and Geron Corporation could all see big gains next week. Here's why.

  • GlobeNewswire25 days ago

    Amarin’s REDUCE-IT™ Clinical Study Now Positioned to be Next Large Cardiovascular Outcomes Study to Report Results

    REDUCE-IT Study Remains On-Track for Report of Top-Line Results Before the End of September 2018. BEDMINSTER, N.J., and DUBLIN, Ireland, Aug. 26, 2018-- Amarin Corporation plc, a biopharmaceutical company ...

  • GlobeNewswirelast month

    New Research Coverage Highlights pdvWireless, Fortuna Silver Mines, Nordic American Tankers, Amarin, Himax Technologies, and Retrophin — Consolidated Revenues, Company Growth, and Expectations for 2018

    NEW YORK, Aug. 21, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of pdvWireless, ...

  • Better Speculative Biotech Stock: Amarin Corporation vs. Geron Corporation
    Motley Foollast month

    Better Speculative Biotech Stock: Amarin Corporation vs. Geron Corporation

    Amarin and Geron are both racing toward major binary events that could pay off for early shareholders in a big way.

  • Thomson Reuters StreetEventslast month

    Edited Transcript of AMRN earnings conference call or presentation 1-Aug-18 11:30am GMT

    Q2 2018 Amarin Corporation PLC Earnings Call

  • This Small-Cap Biotech Is Poised for Eye-Popping Gains
    Motley Fool2 months ago

    This Small-Cap Biotech Is Poised for Eye-Popping Gains

    Vascepa's all-important cardiovascular-outcomes trial is less than two month's away from a top-line readout.

  • Associated Press2 months ago

    Amarin: 2Q Earnings Snapshot

    On a per-share basis, the Dublin-based company said it had a loss of 12 cents. Losses, adjusted for stock option expense, were 10 cents per share. The results did not meet Wall Street expectations. The ...

  • GlobeNewswire2 months ago

    Amarin Reports Second Quarter 2018 Financial Results and Provides Update on Operations

    REDUCE-IT™ Study On-Track for Reporting Top-Line Results by the End of September 2018. Management to Host Conference Call at 7:30 a.m. ET Today. BEDMINSTER, N.J., and DUBLIN, Ireland, Aug. 01, 2018-- Amarin ...

  • GlobeNewswire2 months ago

    Amarin Announces Approval for Vascepa® in United Arab Emirates

    BEDMINSTER, N.J. and DUBLIN, Ireland, July 26, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, along with its commercial partner, Biologix FZCo, a pioneer in the distribution of pharmaceutical and biological products in the Middle East and North Africa (MENA) region, today announced that United Arab Emirates (UAE) Ministry of Health and Prevention has approved Vascepa® (icosapent ethyl) capsules as a prescription medication for use as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (TG 500 mg/dL) hypertriglyceridemia in the UAE. This approval is a result of the collaborative effort by the parties since the start of their 2016 agreement to register and commercialize Vascepa in multiple countries in the MENA region.

  • GlobeNewswire2 months ago

    Amarin to Report Second Quarter 2018 Results and Host Conference Call on August 1, 2018

    Amarin Corporation plc (AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced that it will host a conference call with members of Amarin senior management to discuss the company's second quarter 2018 financial results and provide an operational update on August 1 at 7:30 a.m. EDT. Investors and others should note that Amarin communicates with its investors and the public using the company website (http://www.amarincorp.com/), the investor relations website (http://investor.amarincorp.com/), including but not limited to investor presentations and investor FAQs, Securities and Exchange Commission filings, press releases, public conference calls and webcasts.  The information that Amarin posts on these channels and websites could be deemed to be material information.  As a result, Amarin encourages investors, the media, and others interested in Amarin to review the information that is posted on these channels, including the investor relations website, on a regular basis.  This list of channels may be updated from time to time on Amarin’s investor relations website and may include social media channels.  The contents of Amarin’s website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.

  • 3 Top Biotech Stocks to Buy Right Now
    Motley Fool2 months ago

    3 Top Biotech Stocks to Buy Right Now

    This could be a good time to add a profit-friendly play, a clinical-stage upstart, and a make-or-break biotech to your portfolio.

  • Is Now the Perfect Time to Buy Amarin Corporation Stock?
    Motley Fool2 months ago

    Is Now the Perfect Time to Buy Amarin Corporation Stock?

    Amarin's next major clinical catalyst is close at hand, but investors may want to stick to the sidelines with this high-risk stock.

  • ACCESSWIRE3 months ago

    Breakfast Technical Briefing on Amarin and Three Other Additional Biotech Stocks

    On Friday, June 29, 2018, US markets saw broad based gains with six out of nine sectors finishing the trading sessions in green. All you have to do is sign up today for this free limited time offer by clicking the link below.

  • Why Amarin Rose ~10% Yesterday
    Market Realist3 months ago

    Why Amarin Rose ~10% Yesterday

    On June 28, Amarin (AMRN) stock rose ~10% after the company announced the occurrence of the last patient visit in its REDUCE-IT study, a long-term cardiovascular outcome study, of its fish oil product Vascepa. Amarin’s Vascepa was approved by the FDA (U.S. Food and Drug Administration) in 2012. Despite the large number of Americans having high triglyceride levels and the potentially high patient base for Vascepa, the company is still seeing lower-than-expected sales from the pill.

  • Why Amarin Corporation Zoomed 10% Higher Today
    Motley Fool3 months ago

    Why Amarin Corporation Zoomed 10% Higher Today

    Big news is fast-approaching for its one and only commercial-stage drug.

  • GlobeNewswire3 months ago

    Amarin Reports Last Patient Study Visit Has Occurred, an Important Step Towards Completion of REDUCE-IT™ Cardiovascular Outcomes Study

    Amarin Corporation plc (AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced that the last patient study visit has occurred in its potential landmark cardiovascular outcomes study, REDUCE-IT™.  The company also reiterated that it anticipates having top-line results for this important study reported before the end of Q3 2018. As is typical of large, multi-national, long-term outcomes studies, the final steps preceding REDUCE-IT completion include resolving remaining queries to contribute to a robust and accurate database.  This “cleaning” process is characteristically intensive and time consuming.

  • GlobeNewswire3 months ago

    Real-World Data Supports Association Between High Triglyceride Levels and Increased Cardiovascular Events and Healthcare Costs in People with Diabetes Mellitus

    BEDMINSTER, N.J. and DUBLIN, Ireland, June 25, 2018-- Amarin Corporation plc, a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, ...